Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd
October 15, 2015 9:52 AM EDTRoth Capital reiterated a Buy rating and $50.00 price target on Sarepta Therapeutic (NASDAQ: SRPT) as the advisory meeting has been set for January 22nd.
Analyst Debjit Chattopadhyay commented, "The PDUFA remains February 26th, 2016, but the delayed committee meeting has handed the bears a new... More
AdCom Changes Gives Sarepta Therapeutic (SRPT) Prep Time; Recommends Owning Into Briefing Doc Release
October 15, 2015 8:00 AM EDTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying the January 22 Eteplirsen review gives the company more prep time. The analyst recommends owning the stock into drisapersen's briefing document release.
Marai commented, "Oct. 14, 2015, the FDA... More
Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMD
October 14, 2015 12:44 PM EDTSarepta Therapeutics (NASDAQ: SRPT) announced the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is tentatively scheduled to review Sareptas New Drug Application (NDA) for eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD) amenable to... More
